GlassScriptPhysician profile
Kelly L Baker
NPI 1174567598
$6,746.27
in general payments reported to CMS, 2019-2025
47 companies · $993 in 2025
The $993 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $504 · 2021: $767 · 2022: $1,225 · 2023: $1,252 · 2024: $1,493 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,738.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $899.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $827.52 | 2019-2025 | |
| Abbott Laboratories | $656.24 | 2021-2025 | Freestyle Libre 3, Eterna, Proclaim |
| Amgen INC. | $572.46 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $565.64 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $459.09 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $349.00 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $309.43 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Vanda Pharmaceuticals INC. | $182.13 | 2024-2025 | Fanapt |
| Biohaven Pharmaceutical Holding Company LTD. | $175.71 | 2022 | |
| Xeris Pharmaceuticals, INC. | $131.87 | 2021-2025 | Gvoke Hypopen |
| Daiichi Sankyo INC. | $131.71 | 2019-2023 | Injectafer |
| Sanofi-Aventis U.S. LLC | $119.12 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.02 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $109.25 | 2021-2025 | Eliquis, Camzyos |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.